Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cipro Inhale · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Cipro Inhale (Ciprofloxacin, BAYQ3939) | DRUG | 32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation |
Inclusion Criteria: * Adult subjects with COPD, 40 - 75 years of age * All subjects must have a diagnosis of COPD and must have airway obstruction with a post-bronchodilator Forced Expiratory Volume in 1 sec (FEV1) of \>/= 30% and \<= 80% of predicted and a post-bronchodilator FEV1 / Forced Vital C...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Cipro Inhale is an investigational inhaled formulation of ciprofloxacin, a small molecule antibiotic developed by Bayer AG. It is being studied for infection, including use in patients with chronic obstructive pulmonary disease. It is delivered as an inhalation powder rather than by oral or intravenous administration.
Cipro Inhale is being developed for the treatment of infection, with clinical study conducted in subjects with chronic obstructive pulmonary disease. It is an investigational product and has not been established as a marketed treatment. Its intended use is delivery of ciprofloxacin directly to the lungs via inhalation powder.
Cipro Inhale is developed by Bayer AG, which trades on the OTC market under the ticker BAYRY. Bayer is the sponsor of the clinical program for this inhaled ciprofloxacin formulation.
Cipro Inhale is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The program remains investigational and has not been approved by the FDA.
Cipro Inhale has been studied in one completed Phase 1 trial, NCT01168895. That randomized, double-blind, controlled study enrolled 12 participants in Germany, including healthy volunteers aged 40 years and older, and evaluated safety, tolerability, and pharmacokinetics of single inhaled doses of 50 mg and 75 mg ciprofloxacin inhalation powder in subjects with chronic obstructive pulmonary disease.
Yes. Cipro Inhale is also known as ciprofloxacin and by the development code BAYQ3939. Ciprofloxacin is the active small molecule antibiotic, and Cipro Inhale refers to the inhaled powder formulation of that compound being developed by Bayer AG.